Overview

The Surveillance and Pharmacogenomics Initiative for Adverse Drug Reactions (SAPhIRE) program is funded by the Biomedical Research Council (BMRC) of A*STAR, Singapore to improve drug safety by developing an active surveillance network for adverse drug reaction (ADR) monitoring and discovery of genomic biomarkers that are predictive of specific ADRs.

SAPhIRE seeks to strengthen collaborations among genomic and bioinformatic scientists, clinicians, health economists, and regulators to significantly aid in the translation and implementation of robust, validated pharmacogenomics biomarkers with demonstrated cost-effectiveness. We will build on the strong example of successful implementation of genetic testing for HLA*B-1502 prior to carbamazepine use in Singapore.

Objective

ADR Detection
from EMRs

Establishing an active surveillance infrastructure for ADRs in Singapore; developing tools for informatics mining of electronic medical records

ADRs in Asian
Population

The discovery and validation of genomic biomarkers for ADRs in Asian population; advancing prospective and retrospective studies to investigate ADR for two commonly used classes of drugs,

ADR Clinical
Testing

Development of clinical grade diagnostic assays of genomic biomarkers for ADR clinical testing.

This new initiative is built on the strategic partnership between BMRC and the Health Sciences Authority, as well as close collaboration with local hospitals. The SAPhIRE program is co-led by the Dr Jianjun Liu at the Genome Institute of Singapore (GIS) and Dr Liam Brunham at the Translational Laboratory for Genetic Medicine (TLGM).

Steering Committee

Programme Lead

Jianjun LIU, Ph.D.
Senior Group Leader, Human Genetics and Deputy Director, Research Programmes, Genome Institute of Singapore, A*STAR

Programme Lead

Liam R. Brunham, MD, Ph.D., FRCP
Assistant Principal Investigator, Translational Laboratory for Genetic Medicine, A*STAR  

Programme Manager

Michael David WINTHER, Ph.D.
Senior Project Manager, Genome Institute of Singapore, A*STAR

Scientific Review Committee

David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics, Head of Department of Molecular and Clinical Pharmacology, The Wolfson Centre for Personalised Medicine, University of Liverpool
Professor of Medicine and Pharmacology Director, Oates Institute for Experimental Therapeutics, Assistant Vice-Chancellor for Personalized Medicine Vanderbilt University School of Medicine
Dean at the Lee Kong Chian School of Medicine (LKCMedicine) in Singapore, previously the Head of Medical School at the University of Melbourne in Australia
Professor of Pharmacology, National University of Singapore, Associate Staff, Clinical Pharmacology, National University Hospital